Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Gain Therapeutics (GANX) FCF Margin (2020 - 2023)

Gain Therapeutics (GANX) has 4 years of FCF Margin data on record, last reported at 7663.03% in Q1 2023.

  • For Q1 2023, FCF Margin fell 220772.0% year-over-year to 7663.03%; the TTM value through Dec 2023 reached 34217.53%, down 2364633.0%, while the annual FY2023 figure was 34217.53%, 2305114.0% down from the prior year.
  • FCF Margin reached 7663.03% in Q1 2023 per GANX's latest filing, down from 5358.05% in the prior quarter.
  • Across five years, FCF Margin topped out at 4243.15% in Q2 2021 and bottomed at 53869.71% in Q1 2021.
  • Average FCF Margin over 4 years is 15321.75%, with a median of 11296.8% recorded in 2020.
  • Peak YoY movement for FCF Margin: plummeted -4251480bps in 2021, then skyrocketed 4841440bps in 2022.
  • A 4-year view of FCF Margin shows it stood at 14475.47% in 2020, then tumbled by -137bps to 34240.35% in 2021, then surged by 84bps to 5358.05% in 2022, then crashed by -43bps to 7663.03% in 2023.
  • Per Business Quant database, its latest 3 readings for FCF Margin were 7663.03% in Q1 2023, 5358.05% in Q2 2022, and 5455.31% in Q1 2022.